Products

Mistaurin 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Precision Hematology Mistaurin 25 mg Capsule is a high-efficacy, multi-targeted kinase inhibitor containing the active pharmaceutical ingredient Midostaurin. It is a breakthrough therapy in the field of hematology, specifically engineered to target malignant cells in patients with Acute Myeloid Leukemia (AML) and rare systemic mast cell disorders. By inhibiting the signaling pathways that drive cancer cell proliferation, Mistaurin has become a vital component of modern oncology protocols worldwide. Therapeutic Indications and Clinical Usage Mistaurin 25 mg is extensively utilized across international oncology centers for: FLT3-Mutation Positive AML: Indicated for newly diagnosed adult patients with Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive, used in combination with standard induction and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted treatment for patients with this rare condition involving the overproduction of mast cells in the bone marrow and other organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this aggressive form of leukemia to inhibit the survival of malignant mast cells. Mechanism of Action: How Mistaurin 25mg Works Midostaurin, the active agent in Mistaurin, works by blocking several enzymes (kinases) on the surface and inside of cancer cells: FLT3 Receptor Inhibition: In AML, it targets the FLT3 receptor, which, when mutated, sends constant “grow“ signals to leukemic cells. KIT Kinase Targeting: In mast cell disorders, it inhibits the KIT receptor tyrosine kinase, which is responsible for the uncontrolled growth of mast cells. Broad Spectrum Blockade: It also inhibits other kinases like PDGFR and VEGFR, disrupting the essential signals cancer cells need to survive and build new blood vessels. Apoptosis Induction: By disrupting these signaling pathways, Mistaurin triggers programmed cell death (apoptosis) and effectively slows the progression of the disease. Dosage and Administration Guidelines Dosing for AML: The standard recommended dose is 50 mg (two 25 mg capsules) taken twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with a glass of water. They should not be crushed, chewed, or opened. With Food: Mistaurin should always be taken with food to minimize gastrointestinal side effects and improve absorption. Cycle Management: The duration of treatment is strictly determined by the treating oncologist based on the patient's clinical response and tolerability. Safety Profile and Professional Monitoring Treatment with Mistaurin 25 mg requires vigilant clinical oversight: 1. Gastrointestinal Management Nausea and vomiting are common. Doctors often prescribe anti-emetic medications before the dose to ensure patient comfort and adherence. 2. Respiratory Health Midostaurin may cause lung inflammation (interstitial lung disease). Patients should report any new or worsening cough or shortness of breath immediately. 3. Hematological Monitoring Common side effects include febrile neutropenia (low white blood cells with fever). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection risks. 4. Cardiac Vigilance In some cases, the drug may affect the heart's rhythm (QT prolongation). Periodic ECG monitoring may be recommended for certain patients. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Mstarin 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Precision Hematology Mstarin 25mg Capsule is a high-efficacy, multi-targeted kinase inhibitor containing the active pharmaceutical ingredient Midostaurin. It is a breakthrough therapy in the field of hematology, specifically engineered to target malignant cells in patients with Acute Myeloid Leukemia (AML) and rare systemic mast cell disorders. By inhibiting the signaling pathways that drive cancer cell proliferation, Mstarin has become a vital component of modern oncology protocols worldwide. Therapeutic Indications and Clinical Usage Mstarin 25mg is extensively utilized across international oncology centers for: FLT3-Mutation Positive AML: Indicated for newly diagnosed adult patients with Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive, used in combination with standard induction and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted treatment for patients with this rare condition involving the overproduction of mast cells in the bone marrow and other organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this aggressive form of leukemia to inhibit the survival of malignant mast cells. Mechanism of Action: How Mstarin 25mg Works Midostaurin, the active agent in Mstarin, works by blocking several enzymes (kinases) on the surface and inside of cancer cells: FLT3 Receptor Inhibition: In AML, it targets the FLT3 receptor, which, when mutated, sends constant “grow“ signals to leukemic cells. KIT Kinase Targeting: In mast cell disorders, it inhibits the KIT receptor tyrosine kinase, which is responsible for the uncontrolled growth of mast cells. Broad Spectrum Blockade: It also inhibits other kinases like PDGFR and VEGFR, disrupting the essential signals cancer cells need to survive and build new blood vessels. Apoptosis Induction: By disrupting these signaling pathways, Mstarin triggers programmed cell death (apoptosis) and effectively slows the progression of the disease. Dosage and Administration Guidelines Dosing for AML: The standard recommended dose is 50mg (two 25mg capsules) taken twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with a glass of water. They should not be crushed, chewed, or opened. With Food: Mstarin should always be taken with food to minimize gastrointestinal side effects and improve absorption. Cycle Management: The duration of treatment is strictly determined by the treating oncologist based on the patient's clinical response and tolerability. Safety Profile and Professional Monitoring Treatment with Mstarin 25mg requires vigilant clinical oversight: 1. Gastrointestinal Management Nausea and vomiting are common. Doctors often prescribe anti-emetic medications before the dose to ensure patient comfort and adherence. 2. Respiratory Health Midostaurin may cause lung inflammation (interstitial lung disease). Patients should report any new or worsening cough or shortness of breath immediately. 3. Hematological Monitoring Common side effects include febrile neutropenia (low white blood cells with fever). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection risks. 4. Cardiac Vigilance In some cases, the drug may affect the heart's rhythm (QT prolongation). Periodic ECG monitoring may be recommended for certain patients. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Security: Keep in the original blister pack to protect from moisture and light. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Staurinz 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Precision Hematology Staurinz 25 mg Capsule is a high-efficacy, multi-targeted kinase inhibitor containing the active pharmaceutical ingredient Midostaurin. It is a breakthrough therapy in the field of hematology, specifically engineered to target malignant cells in patients with Acute Myeloid Leukemia (AML) and rare systemic mast cell disorders. By inhibiting the signaling pathways that drive cancer cell proliferation, Staurinz has become a vital component of modern oncology protocols worldwide. Therapeutic Indications and Clinical Usage Staurinz 25 mg is extensively utilized across international oncology centers for: FLT3-Mutation Positive AML: Indicated for newly diagnosed adult patients with Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive, used in combination with standard induction and consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted treatment for patients with this rare condition involving the overproduction of mast cells. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this aggressive form of leukemia to inhibit the survival of malignant mast cells. Mechanism of Action: How Staurinz 25mg Works Midostaurin, the active agent in Staurinz, works by blocking several enzymes (kinases) on the surface of cancer cells: FLT3 Receptor Inhibition: In AML, it targets the FLT3 receptor, which, when mutated, sends constant grow signals to leukemic cells. KIT Kinase Targeting: In mast cell disorders, it inhibits the KIT receptor tyrosine kinase, which is responsible for the uncontrolled growth of mast cells. Apoptosis Induction: By disrupting these signaling pathways, Staurinz triggers programmed cell death (apoptosis) and effectively slows the progression of the disease. Dosage and Administration Guidelines Dosing for AML: The standard recommended dose is 50 mg (two 25 mg capsules) taken twice daily on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with a glass of water. They should not be crushed, chewed, or opened. With Food: Staurinz should always be taken with food to minimize gastrointestinal side effects and improve absorption. Cycle Management: The duration of treatment is strictly determined by the treating oncologist based on the patient's clinical response and tolerability. Safety Profile and Professional Monitoring Treatment with Staurinz 25 mg requires vigilant clinical oversight: 1. Gastrointestinal Management Nausea and vomiting are common. Doctors often prescribe anti-emetic medications before the dose to ensure patient comfort. 2. Respiratory Health Tauritmo may cause lung inflammation (interstitial lung disease). Patients should report any new or worsening cough or shortness of breath immediately. 3. Hematological Monitoring Common side effects include febrile neutropenia (low white blood cells with fever). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection risks. 4. Cardiac Vigilance In some cases, the drug may affect the heart's rhythm (QT prolongation). Periodic ECG monitoring may be recommended for certain patients. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°C). Security: Keep in the original blister pack to protect from moisture and light. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tauritmo 25mg Capsule (Midostaurin): Advanced Kinase Inhibitor for Hematologic Malignancies Tauritmo 25mg Capsule is a sophisticated anti-cancer medication containing the active ingredient Midostaurin. It belongs to a specialized class of drugs known as multikinase inhibitors. Designed for precision oncology, Tauritmo targets specific proteins that signal cancer cells to grow and divide, making it a critical component in the treatment of Acute Myeloid Leukemia (AML) and various rare systemic mast cell disorders. Therapeutic Indications and Clinical Usage Tauritmo 25mg is extensively utilized across international oncology centers for: Acute Myeloid Leukemia (AML): Specifically indicated for newly diagnosed adult patients who test positive for the FLT3 mutation. It is used in combination with standard cytarabine and daunorubicin induction and high-dose cytarabine consolidation chemotherapy. Aggressive Systemic Mastocytosis (ASM): Targeted therapy for patients with this rare condition characterized by the accumulation of abnormal mast cells in organs. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN): Used to manage complex cases where mastocytosis occurs alongside other blood cancers. Mast Cell Leukemia (MCL): Prescribed for this highly aggressive form of leukemia to inhibit the proliferation of malignant mast cells. The Mechanism: How Midostaurin Works Tauritmo exerts its therapeutic effects by inhibiting multiple receptor tyrosine kinases: FLT3 Inhibition: It blocks the mutant FLT3 receptor signaling, which is responsible for the rapid, uncontrolled proliferation of leukemic blasts in AML patients. KIT Receptor Targeting: By inhibiting wild-type and D816V mutant KIT kinases, Tauritmo effectively suppresses the survival and growth of abnormal mast cells. Broad Kinase Blockade: It also targets PDGFR (platelet-derived growth factor receptor) and several other kinases, disrupting the essential “growth signals“ cancer cells need to survive. Cell Cycle Arrest: The inhibition leads to programmed cell death (apoptosis) and prevents the spread of malignancy to other organs. Dosage and Administration Guidelines Dosing Schedule: For AML, the standard dose is 50mg (two 25mg capsules) twice daily (every 12 hours) on specific days of the chemotherapy cycle. Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. With Food: To reduce the risk of gastrointestinal distress, Tauritmo should always be taken with a meal. Renal and Hepatic Assessment: While generally stable, patients with severe hepatic or renal impairment require careful monitoring during therapy. Safety Profile and Side Effect Management As a potent targeted therapy, Tauritmo 25mg requires vigilant clinical monitoring: 1. Gastrointestinal Support Nausea and vomiting are the most frequently reported side effects. Prophylactic anti-emetic medications are often prescribed to ensure patient compliance and comfort. 2. Hematological Monitoring Commonly associated with febrile neutropenia (fever with low white blood cell count). Regular Complete Blood Counts (CBC) are mandatory to monitor for signs of infection. 3. Respiratory Vigilance Tauritmo may cause lung problems (interstitial lung disease/pneumonitis). Patients must report any new or worsening cough, shortness of breath, or chest pain immediately. 4. General Side Effects Other symptoms include musculoskeletal pain, headache, fatigue, and elevated blood sugar levels. Proper hydration and symptomatic management are standard clinical protocols. Storage and Handling Instructions Temperature: Store at room temperature, below 30°C (86°F). Protection: Keep capsules in their original blister packaging to protect them from moisture and light. Handling: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tepmetko 225mg Tablet (Tepotinib): Advanced Precision Therapy for METex14+ NSCLC Tepmetko 225 mg Tablet is a breakthrough oral precision medicine containing the active substance Tepotinib. It is a highly selective, once-daily MET (mesenchymal-epithelial transition) inhibitor specifically engineered to treat adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) that harbors MET exon 14 (METex14) skipping alterations. As the first oral MET inhibitor approved globally for this specific genetic driver, Tepmetko offers a targeted alternative to traditional chemotherapy, focusing directly on the molecular cause of tumor growth. Therapeutic Indications and Clinical Use Tepmetko 225mg is authorized for use across major international oncology centers for: Metastatic NSCLC (METex14+): Indicated for adult patients whose lung cancer has spread to other parts of the body and carries the METex14 skipping mutation. Treatment-Naïve & Previously Treated Patients: It is effective both as a first-line therapy and for patients whose cancer has progressed after receiving prior treatments such as immunotherapy or platinum-based chemotherapy. Advanced/Unresectable Disease: Utilized when the cancer is locally advanced and cannot be removed by surgery. The Mechanism: How Tepmetko 225mg Works Tepmetko belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Its action is highly specific: MET Pathway Inhibition: In certain lung cancers, the MET gene is mutated (METex14 skipping), causing the MET protein to stay “on“ and signal cells to divide uncontrollably. Targeted Blocking: Tepotinib attaches to the abnormal MET protein inside the cancer cells, effectively blocking the survival signals. Tumor Control: By inhibiting this pathway, Tepmetko slows or stops the growth and spread of the cancer, often leading to significant tumor shrinkage (objective response). Dosage and Administration Guidelines Standard Daily Dose: The recommended therapeutic dose is 450 mg, taken as two 225 mg tablets once daily. Method of Intake: Tablets must be swallowed whole with food to ensure optimal absorption. Do not chew, crush, or break the tablets. Dose Modifications: If a patient experiences intolerable side effects, an oncologist may reduce the dose to one 225 mg tablet daily or temporarily interrupt treatment. Missed Dose: If a dose is missed, it can be taken as soon as remembered on the same day, unless the next dose is due within 8 hours. Safety Profile and Professional Monitoring Treatment with Tepmetko 225 mg requires regular clinical supervision to manage the following: 1. Edema (Fluid Retention) The most common side effect (occurring in over 50% of patients) is peripheral edema, characterized by swelling in the ankles, feet, or hands. This is typically managed with salt restriction, leg elevation, or dose adjustments. 2. Interstitial Lung Disease (ILD) / Pneumonitis Though rare, Tepmetko can cause serious or life-threatening lung inflammation. Patients must immediately report new or worsening shortness of breath, cough, or fever. 3. Hepatotoxicity (Liver Health) Tepmetko may cause elevations in liver enzymes (ALT/AST). Liver function tests are mandatory before starting treatment and periodically throughout the therapy (every 2 weeks for the first 3 months). 4. Pancreatic Toxicity Elevations in amylase and lipase levels may occur. Monitoring of these levels is recommended to prevent pancreatic complications. 5. Common Side Effects Other frequently reported symptoms include fatigue, nausea, diarrhea, decreased appetite, and increased blood creatinine levels (a sign of kidney function changes). Storage and Global Handling Temperature: Store below 30°C (86°F) in a dry place. Original Packaging: Keep tablets in the original blister pack to protect them from moisture. Shelf Life: Typically has a shelf life of 30 months when stored correctly. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lynide 25 mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Hetero Healthcare Ltd., a global leader in life-saving medications, Lynide 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lynide 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lynide 25mg Works Lynide exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For Multiple Myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lynide 25mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are often prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lynide. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care and adequate hydration. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin exposure to the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenome 25 mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. As a structural analogue of thalidomide, Lenome 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lenome 25 mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lenome 25mg Works Lenome exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenome 25 mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lenome. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care, adequate hydration, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the capsules directly to avoid accidental skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenmid 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Cipla Ltd., a global pharmaceutical leader, Lenmid 25mg is recognized for its high efficacy, safety standards, and role in extending survival rates for patients worldwide. Therapeutic Indications and Clinical Usage Lenalidomide 25 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for newly diagnosed patients or those who have failed at least one prior therapy. It is also the gold standard for maintenance therapy post-autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for transfusion-dependent anemia caused by low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies. Follicular & Marginal Zone Lymphoma: Often used in combination with Rituximab for patients previously treated for these indolent lymphomas. Mechanism of Action: How Lenmid 25mg Works Lenmid exerts its anti-cancer effects through a multi-faceted biological approach: Direct Cytotoxicity: It binds to the cereblon E3 ubiquitin ligase complex, leading to the degradation of essential transcription factors, which triggers apoptosis (programmed cell death) in malignant cells. Immune System Enhancement: It stimulates the production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-$gamma$), which enhances the activity of T-cells and Natural Killer (NK) cells to actively destroy tumors. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors like VEGF, effectively starving the tumor of the blood supply it needs to grow. Anti-Inflammatory Action: It reduces the production of pro-inflammatory cytokines such as TNF-$alpha$, altering the bone marrow microenvironment to make it less hospitable for cancer cells. Dosage and Administration Guidelines Standard Regimen: Typically administered in 28-day cycles. In multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day break. Method of Intake: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Timing: Can be taken with or without food, but should be taken at the same time every day to maintain consistent blood levels. Renal Monitoring: Since Lenalidomide is primarily excreted by the kidneys, dosage adjustments are vital for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenmid 25mg involves proactive monitoring of the following: 1. Hematological Support Common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory. If counts drop significantly, a dose reduction or temporary treatment interruption is standard practice. 2. Thromboembolism Prophylaxis Patients taking Lenmid have an increased risk of venous thromboembolism (blood clots). Standard care involves prescribing prophylactic anticoagulants (like aspirin or heparin) concurrently with the medication. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is structurally related to thalidomide and is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Patients may report fatigue, diarrhea, muscle cramps, or skin rashes. These are typically managed through adequate hydration, supportive care, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Handling: Caregivers should handle capsules with care and avoid direct skin contact with the powder inside Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383

Lenakast 25mg Capsule (Lenalidomide): Comprehensive Clinical Profile & Global Supply Guide Lenakast 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. As a structural analogue of thalidomide, Lenakast 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Manufactured by Aprazer Healthcare, Lenakast is a trusted choice for oncology centers worldwide. Therapeutic Indications and Clinical Usage Lenakast 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lenakast 25mg Works Lenakast exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-α and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenakast 25mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lenakast. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care, adequate hydration, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the capsules directly to avoid accidental skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ WHO-GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Laviat 25mg Capsule (Lenalidomide): Comprehensive Clinical Profile & Global Export Guide Laviat 25 mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, designed to treat various plasma cell dyscrasias and specific blood cancers. As a structural analogue of thalidomide, Laviat 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Laviat 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates. The Mechanism: How Laviat 25mg WorksLaviat exerts its anti-cancer effects through a sophisticated multi-pathway. mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-$alpha$ and various Interleukins. Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels in the bloodstream. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Laviat 25 mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or pulmonary embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Laviat. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care and adequate hydration. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the caps Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Braunamide 25mg Capsule (Lenalidomide): Comprehensive Clinical Overview & Global Supply GuideBraunamide 25 mg Capsule is a potent immunomodulatory imide drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, designed to treat various plasma cell dyscrasias and specific blood cancers. As a structural analogue of thalidomide, Braunamide 25 mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Braunamide 25 mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also used as a maintenance therapy following autologous stem cell transplantation (ASCT).Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality.Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib.Follicular Lymphoma & Marginal Zone Lymphoma: Used in combination with rituximab for previously treated patients.Mechanism of Action: How Braunamide 25mg WorksBraunamide exerts its anti-cancer effects through a sophisticated multi-pathway mechanism:Immune Modulation: it enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's ability to destroy malignant cells.Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels that tumors need to survive. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) in hematopoietic tumor cells .Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-$alpha$, IL-6, and IL-12.Dosage and Administration GuidelinesCycle-Based Dosing: Typically administered in 28-day cycles. For Multiple Myeloma, the common dose is 25mg taken orally once daily on Days 1–21, followed by a 7-day rest period.Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed.Consistency: It can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels .Renal Adjustment: Since the drug is primarily excreted by the kidneys, dosage adjustments are necessary for patients with impaired renal function.Safety Profile and Side Effect ManagementClinical management of Braunamide 25mg requires vigilant oversight: Hematological Monitoring: The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. Venous Thromboembolism (VTE): There is a significantly increased risk of blood clots. Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Braunamide. Embryo-Fetal Toxicity: Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for both male and female patients of reproductive potential.General Effects: Patients may experience diarrhea, fatigue, skin rashes, or muscle cramps, which are usually managed with supportive care.Storage and HandlingTemperature: Store at room temperature, 20°C to 25°C (68°F to 77°F).Security: Keep in the original blister pack to protect from light and moisture.Handling: Caregivers should wear gloves if handling the capsules directly to avoid skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Pomavia 2 mg Capsule (Pomalidomide): Comprehensive Clinical Profile and Global Export Solutions Pomavia 2 mg Capsule is a highly potent immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Pomalidomide. Specifically engineered for patients with complex hematological malignancies, Pomavia represents a third-generation treatment option for those who have developed resistance to earlier therapies. As a vital component in modern oncology, Pomavia is recognized for its ability to target cancer cells through multiple biological pathways. Therapeutic Indications and Clinical Use Pomavia 2 mg is primarily indicated for the following medical conditions: Relapsed and Refractory Multiple Myeloma (RRMM): It is prescribed for adult patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression. Combination Regimens: For maximum therapeutic effect, Pomavia is typically used in combination with low-dose Dexamethasone. Kaposi Sarcoma: In specific clinical scenarios, it is utilized for patients with AIDS-related Kaposi Sarcoma (KS) or for HIV-negative patients who require advanced immunomodulatory intervention. The Mechanism: How Pomavia 2 mg Works The efficacy of Pomavia is rooted in its triple-action mechanism: Tumor Cell Inhibition: It directly binds to the cereblon protein, leading to the degradation of essential transcription factors, which triggers apoptosis (programmed cell death) in malignant cells. Immune System Modulation: It enhances the body’s natural defense by stimulating T-cells and Natural Killer (NK) cells, empowering the immune system to actively hunt and destroy cancer cells. Anti-Angiogenesis: It blocks the development of new blood vessels that tumors rely on for oxygen and nutrients, effectively inhibiting the growth and spread of the disease. Dosage and Administration Guidelines Standard Regimen: The dose is typically 4mg or 2mg taken once daily on days 1–21 of repeated 28-day cycles. Intake Instructions: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed to ensure the medication is released correctly in the body. Timing: It is best taken at the same time each day, with or without food. Monitoring: Treatment continues until disease progression or until a physician determines that the side effects outweigh the clinical benefits. Safety Profile and Patient Management Managing the safety of Pomavia 2 mg is a critical part of the treatment journey: Hematological Monitoring The most common side effects are neutropenia (low white blood cell count) and thrombocytopenia (low platelet count). Regular blood tests (CBC) are mandatory during the first few months of treatment to monitor for infection risks or bleeding. Thromboembolism Prophylaxis Patients taking Pomavia have a heightened risk of blood clots. Standard care involves the use of prophylactic anticoagulants (like aspirin or heparin) to minimize the risk of deep vein thrombosis (DVT) or pulmonary embolism. Infection Control Due to the immunomodulatory nature of the drug, patients may be more susceptible to bacterial or viral infections. Any signs of fever, chills, or persistent cough must be reported to the oncologist immediately. Embryo-Fetal Toxicity Pomalidomide is known to cause severe birth defects. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. Storage and Handling Guidelines Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Protection: Keep capsules in their original blister packaging to shield them from moisture and light. Handling: Caregivers should handle capsules with care and avoid direct skin contact with the powder inside. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383